Shash v. Biogen Inc., 627 F.Supp.3d 84

Background:

Plaintiffs (Shash and Khan) sued Biogen and three executives in a securities-fraud putative class action alleging misleading statements about aducanumab’s efficacy during the Class Period (Oct. 22, 2019–Nov. 6, 2020).
Aducanumab underwent two identical Phase III trials (ENGAGE/Study 301 and EMERGE/Study 302); an independent futility analysis prompted early termination in March 2019.
Biogen performed post-hoc analyses (with FDA collaboration) and publicly represented that EMERGE showed statistically significant benefit at high dose/exposure and that ENGAGE’s negative result was explained by lower exposure; Biogen filed for FDA approval based on those analyses.
The FDA briefing materials published Nov. 4, 2020 included a largely supportive agency review and a dissenting statistical report by reviewer Tristan Massie criticizing the analyses; markets reacted sharply over Nov. 4–9, 2020.
Plaintiffs purchased shares after publication of the briefing materials and Massie report and allege Biogen misstatements (dose-dependence, plaque–clinical correlation, endpoint breadth, regional variation) violated Sections 10(b) and 20(a).
Defendants moved to dismiss; the court granted the motion, concluding the challenged statements were non-actionable opinions, scienter and loss-causation were not adequately pleaded, and related claims failed.

Issues:

Issue	Plaintiff's Argument	Defendant's Argument	Held
Falsity / material misstatements	Biogen misrepresented efficacy by touting post-hoc results (dose/exposure effect, plaque reduction correlation, multiple endpoints, negligible regional effects) while omitting contrary subgroup analyses (Massie).	Statements were opinion/interpretation of complex clinical data and transparently based on post-hoc/topline analyses endorsed by FDA; alternative analyses reflect scientific disagreement.	Statements treated as non-actionable opinions; plaintiffs failed to plead actionable false statements.
Scienter	Defendants knew or recklessly ignored contrary subgroup analyses (Massie) and had motive (company stake in drug).	No facts show defendants believed their public conclusions were false; FDA collaboration and submission make deliberate fraud implausible.	Plaintiffs failed to plead a strong inference of scienter (intent or extreme recklessness).
Loss causation / economic loss	Stock price rise on Nov. 4 was allegedly inflated by misstatements; drop after Nov. 6 Advisory Committee vote corrected the market causing plaintiffs’ losses.	Corrective information (Massie report/briefing materials) published before plaintiffs bought stock; plaintiffs cannot show their purchase relied on concealed facts causing their loss.	Plaintiffs did not adequately plead loss causation; corrective information preceded plaintiffs’ purchases.
Reliance / standing	Plaintiffs reasonably relied because market had not yet digested technical Massie report when they bought.	Plaintiffs bought after publication of the briefing materials and Massie report, so reliance was unreasonable and standing fails.	Court need not decide given other dispositive defects but noted reliance/standing problematic because plaintiffs purchased after disclosure.

Key Cases Cited

Bell Atl. Corp. v. Twombly, 550 U.S. 544 (pleading must be plausible)
Ashcroft v. Iqbal, 556 U.S. 662 (plausibility standard for complaints)
Omnicare, Inc. v. Laborers Dist. Council Constr. Indus. Pension Fund, 575 U.S. 175 (opinion statements can be actionable only if speaker lacks belief or omitted facts render opinion misleading)
Tellabs, Inc. v. Makor Issues & Rights, Ltd., 551 U.S. 308 (holistic scienter inquiry; inference must be at least as compelling as nonfraudulent inference)
Matrixx Initiatives, Inc. v. Siracusano, 563 U.S. 27 (scienter standard; fraud requires material misstatements/omissions)
In re Boston Sci. Corp. Sec. Litig., 686 F.3d 21 (1st Cir. 2012) (PSLRA and Rule 9(b) pleading standards for securities fraud)
Construction Indus. & Laborers Joint Pension Tr. v. Carbonite, Inc., 22 F.4th 1 (1st Cir. 2022) (distinguishing fact vs. opinion and pleading falsity)
Corban v. Sarepta Therapeutics, Inc., 868 F.3d 31 (1st Cir. 2017) (scientific disagreement over trial analysis is non-actionable when reasonable)
City of Edinburgh Council v. Pfizer, Inc., 754 F.3d 159 (3d Cir. 2014) (interpretations of clinical data are opinions; only certain affirmative misstatements are actionable)
Kleinman v. Elan Corp., plc, 706 F.3d 145 (2d Cir. 2013) (post-hoc analyses are exploratory; reasonable methodological disputes are non-actionable)